Long-term data on active surveillance from MSKCC

A presentation at the upcoming annual meeting of the American Urological Association (AUA) will provide data on outcomes of men initially managed on active surveillance at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York over the past 17 years. … READ MORE…

The MEAL study — another update: data coming soon

In October last year we had expressed the hope that data from the Men’s Eating and Living (MEAL) study would be presented at a major medical meeting this year. … READ MORE …

How anxiety affects prostate cancer patients on active surveillance over time

“Anxiety” of different types is a problem associated with every diagnosis of prostate cancer. Such anxiety comes with particular implications for men implementing active surveillance as an initial management strategy after initial diagnosis with very low-, low-, or favorable intermediate-risk prostate cancer. … READ MORE …

Short-term ADT for men on active surveillance?

One paper to be presented at the upcoming annual meeting of the American Urological Association (AUS) gives results from treatment with a 3-month dose of androgen deprivation therapy (ADT) for men with low-risk prostate cancer compared to standard active surveillance. … READ MORE …

On active and proactive surveillance

Once upon a time (and not so long ago) newly diagnosed men with some types of prostate cancer used to think your sitemaster was out of his tiny mind when he would suggest to them that they might be wise to just monitor their situation rather than rush into treatment. … READ MORE …

Improving survival among men with oligorecurrent prostate cancer?

A newly published article in the Journal of Clinical Oncology reports data from a small, randomized, multicenter, Phase II clinical trial comparing active monitoring to treatment of men with recurrent, asymptomatic, oligometastatic prostate cancer. … READ MORE …

Howard’s got the vitamins to prove … something!

In his latest blog post on the MedPage Today web site (which seems to to be spreading way beyond his prostate cancer — successfully managed with active surveillance to date), Howard Wolinsky talks about what it’s costing to keep himself in vitamins (mostly not for his prostate cancer)! … READ MORE …